Search

Cookies

We use cookies to improve your experience. By continuing, you accept our use of cookies.

Business

Laurus Labs Shares Dive 8% After Promoters Sell Rs 500 Crore Worth of Stock

· · 2 min read

Laurus Labs shares fell 8.39% on Monday, closing at Rs 2,217.05, after company promoters sold 20 lakh shares valued at approximately Rs 500 crore. This decline occurred despite the pharmaceutical firm reporting a 126% jump in Q2 FY27 net profit.

Shares of Laurus Labs Ltd experienced a significant decline on Monday, November 16, 2026, plunging 8.39% to settle at Rs 2,217.05. This sharp fall was primarily triggered by the company's promoters offloading 20 lakh shares, a transaction valued at around Rs 500 crore.

The recent dip places the stock 10.66% below its all-time high of Rs 2,481.50, which it achieved just days earlier on November 11. Despite this setback, Laurus Labs has maintained its status as a multibagger stock, having gained an impressive 99.72% year-to-date.

Strong Q2 FY27 Financial Performance

The share price movement contrasts with the company's robust financial results for the second quarter of fiscal year 2027. Laurus Labs reported a substantial 126% year-on-year (YoY) increase in consolidated net profit, reaching Rs 441 crore, up from Rs 195 crore in the corresponding quarter last year.

Revenue also saw strong growth, rising 33% YoY to Rs 2,206 crore from Rs 1,653 crore. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) climbed 78% to Rs 762 crore, indicating healthy operational efficiency.

Expansion and Analyst Outlook

Satyanarayana Chava, Founder and CEO of Laurus Labs, highlighted the company's strategic advancements. "The company operationalised its first commercial scale peptide plant in Vizag utilising cutting edge operating systems and a significant capacity expansion is already under progress to address surging demand for peptide therapeutics," Chava stated. He also noted targeted investments in Oligonucleotides and peptide-resins technologies, enhancing their integrated Contract Development and Manufacturing Organisation (CDMO) offerings.

Nuvama Institutional Equities, a brokerage firm, acknowledged Laurus Labs' strong quarter, noting that the company surpassed its revenue, EBITDA, and PAT estimates by 6%, 16%, and 21% respectively. Nuvama attributed this performance to a richer CDMO mix and operational leverage, pointing out that the company's EBITDA margin reached an all-time high of 34%.

Looking ahead, Nuvama also confirmed that Laurus Labs has maintained its capital expenditure guidance of Rs 3,000 crore for FY27–28, with the majority of these investments directed towards Active Pharmaceutical Ingredients (API) manufacturing.

Related